Does RADIUM RA-223 DICHLORIDE Cause Malignant neoplasm progression? 129 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 129 reports of Malignant neoplasm progression have been filed in association with RADIUM RA-223 DICHLORIDE (Xofigo). This represents 2.7% of all adverse event reports for RADIUM RA-223 DICHLORIDE.
129
Reports of Malignant neoplasm progression with RADIUM RA-223 DICHLORIDE
2.7%
of all RADIUM RA-223 DICHLORIDE reports
12
Deaths
18
Hospitalizations
How Dangerous Is Malignant neoplasm progression From RADIUM RA-223 DICHLORIDE?
Of the 129 reports, 12 (9.3%) resulted in death, 18 (14.0%) required hospitalization, and 1 (0.8%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RADIUM RA-223 DICHLORIDE. However, 129 reports have been filed with the FAERS database.
What Other Side Effects Does RADIUM RA-223 DICHLORIDE Cause?
Prostatic specific antigen increased (449)
Hormone-refractory prostate cancer (441)
Death (376)
Anaemia (324)
Metastases to bone (315)
General physical health deterioration (308)
Fatigue (242)
Haemoglobin decreased (236)
Prostate cancer (234)
Nausea (221)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which RADIUM RA-223 DICHLORIDE Alternatives Have Lower Malignant neoplasm progression Risk?
RADIUM RA-223 DICHLORIDE vs RALOXIFENE
RADIUM RA-223 DICHLORIDE vs RALTEGRAVIR
RADIUM RA-223 DICHLORIDE vs RALTITREXED
RADIUM RA-223 DICHLORIDE vs RAMELTEON
RADIUM RA-223 DICHLORIDE vs RAMIPRIL